Skip to main content

Drug Interactions between adagrasib and risperidone

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

risperiDONE adagrasib

Applies to: risperidone and adagrasib

GENERALLY AVOID: Adagrasib can cause concentration-dependent, prolongation of the QT interval. Coadministration with other agents that can prolong the QT interval may increase the risk of ventricular arrhythmias including torsade de pointes and sudden death. According to cardiac electrophysiology data provided by the manufacturer, the mean (90% CI) QTcF change from baseline was 18 ms at the mean steady-state maximum concentration (Cmax,ss) after administration of adagrasib 600 mg twice daily. In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).

GENERALLY AVOID: Adagrasib may increase the plasma concentrations and adverse effects of sensitive CYP450 2C9, 2D6 or P-glycoprotein (P-gp) substrates. Adagrasib is an inhibitor of CYP450 2C9, 2D6, and P-gp. In pharmacokinetic studies, adagrasib 600 mg twice daily is predicted to increase warfarin (a sensitive CYP450 2C9 substrate) peak plasma concentration (Cmax) and systemic exposure (AUC) by 1.1-fold and 2.9-fold, respectively. Also, adagrasib 600 mg twice daily is predicted to increase dextromethorphan (a sensitive CYP450 2D6 substrate) Cmax and AUC by 1.7-fold and 2.4-fold, respectively. In addition, adagrasib 600 mg twice daily is predicted to increase digoxin (a P-gp substrate) Cmax and AUC by 1.9-fold and 1.5-fold, respectively.

MANAGEMENT: Coadministration of adagrasib with other drugs that can prolong the QT interval and/or are sensitive substrates of CYP450 2C9, 2D6 or P-gp should generally be avoided.

References

  1. (2022) "Product Information. Krazati (adagrasib)." Mirati Therapeutics, Inc.

Switch to consumer interaction data

Drug and food interactions

Major

adagrasib food

Applies to: adagrasib

ADJUST DOSING INTERVAL: Adagrasib can cause concentration-dependent, prolongation of the QT interval. Theoretically, coadministration with grapefruit juice before adagrasib has reached steady-state may significantly increase the plasma concentrations of adagrasib, which is primarily metabolized by CYP450 3A4. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. Inhibition of hepatic CYP450 3A4 may also contribute. The interaction has not been studied with grapefruit juice but has been reported for the potent CYP450 3A4 inhibitor, itraconazole. In a clinical drug interaction study, adagrasib peak plasma concentration (Cmax) and systemic exposure (AUC) were increased by 2.4-fold and 4-fold, respectively following concomitant use of a single dose of adagrasib (200 mg) with itraconazole. No clinically significant differences in the pharmacokinetics of adagrasib at steady state were predicted when used concomitantly with itraconazole. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Increased exposure to adagrasib may increase the risk of adverse effects such as QT prolongation, diarrhea, fatigue, musculoskeletal pain, hepatotoxicity, and renal impairment.

Adagrasib pharmacokinetics were not significantly affected when administered with a high-fat meal.

MANAGEMENT: Although clinical data are lacking, it may be advisable to avoid the consumption of grapefruit or grapefruit juice until adagrasib concentrations have reached steady state (after approximately 8 days). Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Adagrasib may be administered with or without food.

References

  1. (2022) "Product Information. Krazati (adagrasib)." Mirati Therapeutics, Inc.

Switch to consumer interaction data

Moderate

risperiDONE food

Applies to: risperidone

GENERALLY AVOID: Risperidone oral solution is not compatible with either tea or cola. In addition, alcohol may potentiate some of the pharmacologic effects of risperidone. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

MANAGEMENT: Risperidone oral solution should not be mixed with tea or cola. It may be taken with water, coffee, orange juice, or lowfat milk. Patients should also be advised to avoid consumption of alcohol.

References

  1. (2001) "Product Information. Risperdal (risperidone)." Janssen Pharmaceuticals

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.